摘要
恶性肿瘤已成为全球重大的公共卫生问题。目前治疗恶性肿瘤的主要手段包括外科手术,放疗和化疗三种,随着靶向治疗和免疫治疗的迅速发展,延长了患者的生存期,但仍难以治愈。B类Ⅰ型清道夫受体(scavenger receptor class B type Ⅰ,SR-BⅠ)是一种高亲和力的高密度脂蛋白(high density lipoprotein,HDL)受体。研究发现,SR-BⅠ在多种恶性肿瘤中过表达,并且参与肿瘤的增殖、迁移、血管生成和信号调节。SR-BⅠ有望成为恶性肿瘤诊断、预后甚至治疗靶点的潜在标记物。文章就目前SR-BⅠ蛋白与恶性肿瘤关系的研究进展作一综述。
Malignant tumors have become a major public health issue globally.At present,the main methods for treating malignant tumors include surgery,radiotherapy and chemotherapy.With the rapid development of targeted therapy and immunotherapy,the survival period of patients has been extended,but it is still difficult to cure.Scavenger receptor class B typeⅠ(SR-BⅠ)is a high affinity high-density lipoprotein(HDL)receptor.Research has found that SR-BⅠis overexpressed in various malignant tumors and participates in tumor proliferation,migration,angiogenesis,and signal regulation.SR-BⅠis expected to become a potential marker for the diagnosis,prognosis,and even treatment targets of malignant tumors.This review summarizes the current research progress on the relationship between SR-BⅠprotein and malignant tumors.
作者
孙玥彤
薛荣泉
韩立博
Sun Yuetong;Xue Rongquan;Han Libo(Inner Mongolia Clinical Medical College of Inner Mongolia Medical University,Hohhot 010017,China;Department of Hepatobiliary Surgery,Inner Mongolia Autonomous Region People's Hospital,Hohhot 010017,China;Department of Hepatobiliary Surgery,Inner Mongolia Medical University Affiliated Hospital,Hohhot 010050,China)
出处
《国际免疫学杂志》
CAS
2023年第5期569-573,共5页
International Journal of Immunology
基金
内蒙古自治区科技计划项目(2021GG0116)。
关键词
B类Ⅰ型清道夫受体
恶性肿瘤
高密度脂蛋白
Class B type I scavenger receptor
Malignant tumor
High-density lipoprotein
